Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

Authors: Jeremy W. Jacobs, Laura D. Stephens, David M. Chooljian, Deva Sharma, Brian D. Adkins, Garrett S. Booth

Published: 2024-02-27

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27275

Keywords: No keywords found.

Abstract:
No abstract found.

Source: